Almanack Investment Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Almanack Investment Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$666K	Sell	4,209 -1,098	-21%	-$148K	0.08%	135
2026 Q1	$678K	Buy	5,307 +849	+19%	+$106K	0.11%	87
2025 Q4	$544K	Buy	+4,458	New	+$511K	0.09%	93
2021 Q1	–	Sell	-2,455	Closed	-$346K	–	474
2020 Q4	$346K	Buy	2,455 +64	+3%	+$8.2K	0.04%	268
2020 Q3	$292K	Buy	+2,391	New	+$268K	0.04%	299
2018 Q4	–	Sell	-4,980	Closed	-$425K	–	263
2018 Q3	$425K	Buy	4,980 +2,170	+77%	+$210K	0.11%	99
2018 Q2	$267K	Sell	2,810 -2,458	-47%	-$226K	0.12%	79
2018 Q1	$461K	Sell	5,268 -1,484	-22%	-$135K	0.18%	49
2017 Q4	$575K	Buy	6,752 +1,806	+37%	+$151K	0.23%	50
2017 Q3	$428K	Sell	4,946 -8,756	-64%	-$702K	0.21%	52
2017 Q2	$1.06M	Buy	13,702 +8,696	+174%	+$617K	0.59%	45
2017 Q1	$347K	Buy	+5,006	New	+$336K	0.26%	65

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Almanack Investment Partners's XBI Position: Q2 2026 in Review

Almanack Investment Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 21% in Q2 2026, selling an estimated $148K and leaving 4,209 shares worth $666K. The position accounts for 0.08% of the portfolio, ranked #135.

Almanack Investment Partners first reported a position in XBI in Q1 2017 and has held it in 12 quarters since. The position peaked at $1.06M in Q2 2017. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Almanack Investment Partners held 4,209 shares of State Street SPDR S&P Biotech ETF worth $666K as of Q2 2026.
Almanack Investment Partners sold 1,098 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $148K.
State Street SPDR S&P Biotech ETF made up 0.08% of Almanack Investment Partners's portfolio in Q2 2026, its #135 holding.
Almanack Investment Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and has held it in 12 quarters since.
Almanack Investment Partners's State Street SPDR S&P Biotech ETF position peaked at $1.06M in Q2 2017.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.